ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag nonprofit tuberculosis drug development industry

Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Outwitting the Perfect Pathogen
Megan Scudellari | Jan 1, 2014 | 8 min read
Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.
Getting Your Gates
Juhi Yajnik | Nov 1, 2006 | 6 min read
How one company used the growing nonprofit funding pot to jump-start its development program, and how you can do the same.
TB diagnostics initiative launched
Robert Walgate(walgate@scienceanalysed.com) | Jun 2, 2003 | 4 min read
Gates' $30 million for tuberculosis diagnostics causes controversy
Venture Capital, with a Twist
Ted Agres(tagres@the-scientist.com) | Jul 17, 2005 | 5 min read
Jamie Heywood, chief executive of the Amyotrophic Lateral Sclerosis Therapy Development Foundation (ALSTDF), founded the nonprofit biotech company in 1999 after his brother was diagnosed with ALS.
Limited Access To cDNA Database Has Drug Manufacturer Up In Arms
Franklin Hoke | Dec 11, 1994 | 8 min read
Date : December 12, 1994 Incensed that the terms exclude industrial scientists, Merck announces sponsorship of competing project A powerful new, privately held database of human complementary DNA (cDNA) sequences has become available to researchers eager to test its capabilities to rapidly identify new genes. The proposed terms of access to the database, however, exclude pharmaceutical and other industry-affiliated scientists, an
Limited Access To cDNA Database Has Drug Manufacturer Up In Arms
Franklin Hoke | Dec 11, 1994 | 8 min read
Date : December 12, 1994 Incensed that the terms exclude industrial scientists, Merck announces sponsorship of competing project A powerful new, privately held database of human complementary DNA (cDNA) sequences has become available to researchers eager to test its capabilities to rapidly identify new genes. The proposed terms of access to the database, however, exclude pharmaceutical and other industry-affiliated scientists, an
Regulations And Poor Communication Slow Pediatric Vaccine Development
Kathryn Brown | May 26, 1996 | 8 min read
Vaccine Development Well-intentioned immunization efforts ignore economic realities, observers contend. By all accounts, the 1990s should be a monumental decade for pediatric vaccines. Wielding new molecular tools like genetic engineering, scientists can craft safer and more creative vaccines than ever imagined. Yet poor communication and disparate desires among industry players plague the vaccine pipeline, according to insiders. As a result, they say, vaccine R&D is taking a hit, investors
Looking Back At Jenner, Vaccine Developers Prepare For 21st Century
Kathryn Brown | Apr 1, 1996 | 8 min read
This year marks the 200th anniversary of the first vaccine, which was developed against smallpox. As vaccine researchers launch a new century of challenging disease science, they might find inspiration in the simple beginnings of Edward Jenner's discovery. 
Feldbaum to Biotech Leaders: Cooperate and Share
Paula Park | Jul 7, 2002 | 4 min read
Photo: Courtesy of Carl Feldbaum Carl Feldbaum Financiers and biotechnology business leaders suspended their networking for a few minutes at the BIO 2002 annual convention in Toronto as Carl Feldbaum, chairman of the powerful US Biotechnology Industry Organization, urged them to cooperate with their competitors and assist the poor. Feldbaum's 10-point Biotechnology Foreign Policy,1 introduced over a sumptuous lunch, would provide appropriate and affordable vaccines and drugs for developi

Run a Search

ADVERTISEMENT